Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs